Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents : analysis of CVD-REAL data

Show simple item record

dc.contributor.author CVD-REAL Investigators Study Grp
dc.contributor.author Khunti, Kamlesh
dc.contributor.author Kosiborod, Mikhail
dc.contributor.author Kim, Dae Jung
dc.contributor.author Eriksson, Johan G.
dc.contributor.author Fenici, Peter
dc.date.accessioned 2021-09-28T06:08:02Z
dc.date.available 2021-09-28T06:08:02Z
dc.date.issued 2021-07-31
dc.identifier.citation CVD-REAL Investigators Study Grp , Khunti , K , Kosiborod , M , Kim , D J , Eriksson , J G & Fenici , P 2021 , ' Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents : analysis of CVD-REAL data ' , Cardiovascular Diabetology , vol. 20 , no. 1 , 159 . https://doi.org/10.1186/s12933-021-01345-z
dc.identifier.other PURE: 168813934
dc.identifier.other PURE UUID: 0a506b8c-f361-407a-bf45-ddecb795e47f
dc.identifier.other WOS: 000681374800003
dc.identifier.uri http://hdl.handle.net/10138/334647
dc.description.abstract Background Randomized, controlled cardiovascular outcome trials may not be fully representative of the management of patients with type 2 diabetes across different geographic regions. We conducted analyses of data from the multinational CVD-REAL consortium to determine the association between initiation of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and cardiovascular outcomes, including subgroup analyses based on patient characteristics. Methods De-identified health records from 13 countries across three continents were used to identify patients newly-initiated on SGLT-2i or other glucose-lowering drugs (oGLDs). Propensity scores for SGLT-2i initiation were developed in each country, with 1:1 matching for oGLD initiation. In the matched groups hazard ratios (HRs) for hospitalization for heart failure (HHF), all-cause death (ACD), the composite of HHF or ACD, myocardial infarction (MI) and stroke were estimated by country, and pooled using a weighted meta-analysis. Multiple subgroup analyses were conducted across patient demographic and clinical characteristics to examine any heterogeneity in treatment effects. Results Following matching, 440,599 new users of SGLT-2i and oGLDs were included in each group. Mean follow-up time was 396 days for SGLT-2i initiation and 406 days for oGLDs initiation. SGLT-2i initiation was associated with a lower risk of HHF (HR: 0.66, 95%CI 0.58-0.75; p < 0.001), ACD (HR: 0.52, 95%CI 0.45-0.60; p < 0.001), the composite of HHF or ACD (HR: 0.60, 95%CI 0.53-0.68; p < 0.001), MI (HR: 0.85, 95%CI 0.78-0.92; p < 0.001), and stroke (HR: 0.78, 95%CI 0.72-0.85; p < 0.001); regardless of patient characteristics, including established cardiovascular disease, or geographic region. Conclusions This CVD-REAL study extends the findings from the SGLT-2i clinical trials to the broader setting of an ethnically and geographically diverse population, and across multiple subgroups. Trial registration NCT02993614 en
dc.format.extent 15
dc.language.iso eng
dc.relation.ispartof Cardiovascular Diabetology
dc.rights cc_by
dc.rights.uri info:eu-repo/semantics/openAccess
dc.subject Sodium-glucose cotransporter-2 inhibitors
dc.subject Cardiovascular outcomes
dc.subject Heart failure
dc.subject Type 2 diabetes
dc.subject RISK
dc.subject INITIATION
dc.subject THERAPIES
dc.subject MORTALITY
dc.subject TRIALS
dc.subject DEATH
dc.subject ASIA
dc.subject 3121 General medicine, internal medicine and other clinical medicine
dc.title Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents : analysis of CVD-REAL data en
dc.type Article
dc.contributor.organization Clinicum
dc.contributor.organization Research Programs Unit
dc.contributor.organization Johan Eriksson / Principal Investigator
dc.contributor.organization Department of General Practice and Primary Health Care
dc.description.reviewstatus Peer reviewed
dc.relation.doi https://doi.org/10.1186/s12933-021-01345-z
dc.relation.issn 1475-2840
dc.rights.accesslevel openAccess
dc.type.version publishedVersion

Files in this item

Total number of downloads: Loading...

Files Size Format View
Cardiovascular_outcomes_with_sodium_glu...pdf 3.634Mb PDF View/Open

This item appears in the following Collection(s)

Show simple item record